Omics-based biomarkers for the early Alzheimer Disease diagnosis and reliable therapeutic targets development.

CONCLUSION: The assessment of metabolomic/lipidomic, epigenomic and proteomic changes associated with AD to identify early biomarkers in non-invasive samples from well-defined participants groups will potentially allow the advancement in the early diagnosis and improvement of therapeutic interventions. PMID: 30255758 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/30255758?dopt=Abstract

Source: Current Neuropharmacology - September 26, 2018 Category: Drugs & Pharmacology Authors: Pena-Bautista C, Baquero M, Vento M, Chafer-Pericas C Tags: Curr Neuropharmacol Source Type: research